We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+7.51%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.46B
AUM Growth
-$38.8M
Cap. Flow
-$22M
Cap. Flow %
-1.5%
Top 10 Hldgs %
61.18%
Holding
86
New
16
Increased
26
Reduced
28
Closed
12

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$44.8M
2
RGEN icon
Repligen
RGEN
+$29.2M
3
INSP icon
Inspire Medical Systems
INSP
+$21.3M
4
NVO
Novo Nordisk
NVO
+$11.2M
5
HCA icon
HCA Healthcare
HCA
+$10.3M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$61.4M
2
PFE icon
Pfizer
PFE
+$30.6M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$26.2M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$20.1M
5
THC icon
Tenet Healthcare
THC
+$18.5M

Sector Composition

Rank Sector Weight
1 Healthcare 88.85%
2 Miscellaneous 11.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$489B
$137M 9.37%
285,600
-41,200
-13% -$18.5M
GSK icon
2
GSK
GSK
$102B
$134M 9.14%
3,468,080
-303,914
-8% -$12.8M
NTRA icon
3
Natera
NTRA
$47B
$127M 8.7%
1,173,494
-604,557
-34% -$61.4M
INSM icon
4
Insmed
INSM
$25.9B
$77.4M 5.3%
+1,155,588
New +$44.8M
TEVA icon
5
Teva Pharmaceuticals
TEVA
$42.5B
$76.7M 5.25%
4,720,460
-1,304,709
-22% -$20.1M
UTHR icon
6
United Therapeutics
UTHR
$22.1B
$75M 5.13%
235,351
-15,784
-6% -$4.18M
SNDX icon
7
Syndax Pharmaceuticals
SNDX
$1.74B
$74.2M 5.08%
3,613,631
+480,518
+15% +$10.1M
VERA icon
8
Vera Therapeutics
VERA
$2.46B
$73.9M 5.06%
2,043,214
+219,433
+12% +$8.7M
INSP icon
9
Inspire Medical Systems
INSP
$1.78B
$71.3M 4.88%
533,011
+112,312
+27% +$21.3M
RVTY icon
10
Revvity
RVTY
$14.4B
$47.4M 3.24%
451,582
-31,578
-7% -$3.35M
HCA icon
11
HCA Healthcare
HCA
$90.5B
$43.5M 2.98%
135,480
+31,659
+30% +$10.3M
TECH icon
12
Bio-Techne
TECH
$11.3B
$38.9M 2.66%
543,044
-64,643
-11% -$4.76M
HQY icon
13
HealthEquity
HQY
$7.97B
$35.6M 2.44%
413,531
-7,814
-2% -$631K
CYH icon
14
Community Health Systems
CYH
$413M
$27M 1.85%
8,037,470
+56,829
+0.7% +$191K
RGEN icon
15
Repligen
RGEN
$9.95B
$24.5M 1.68%
194,291
+186,054
+2,259% +$29.2M
CLDX icon
16
Celldex Therapeutics
CLDX
$3.07B
$23.4M 1.6%
633,015
-78,100
-11% -$2.95M
IONS icon
17
Ionis Pharmaceuticals
IONS
$10.1B
$21.8M 1.49%
456,881
+80,443
+21% +$3.3M
NVO
18
Novo Nordisk
NVO
$202B
$21M 1.44%
146,956
+84,612
+136% +$11.2M
LLY icon
19
Eli Lilly
LLY
$1.05T
$19.2M 1.32%
21,233
+8,356
+65% +$6.68M
PTGX icon
20
Protagonist Therapeutics
PTGX
$9.34B
$17.5M 1.2%
505,836
+94,358
+23% +$2.76M
SPY icon
21
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$16.8M 1.15%
30,800
+500
+2% +$262K
ARGX icon
22
argenx
ARGX
$64B
$14.9M 1.02%
34,593
-19,925
-37% -$7.63M
HUM icon
23
Humana
HUM
$46.3B
$14.2M 0.97%
38,023
+2,491
+7% +$841K
VTRS icon
24
Viatris
VTRS
$18.8B
$14.1M 0.97%
1,329,282
+12,813
+1% +$142K
ZIMV
25
DELISTED
ZimVie
ZIMV
$14M 0.96%
767,659
+203,161
+36% +$3.33M
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2024 Portfolio in Review

As of Q2 2024, Eversept Partners held 86 positions worth $1.46B, down 2.6% from $1.5B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Eversept Partners's Q2 2024 filing shows 16 new, 26 increased, 28 reduced and 12 closed positions. Its largest new stake was Insmed: 1,155,588 shares worth $77.4M. The largest sale was Natera, an estimated $61.4M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 89% a quarter earlier, followed by Miscellaneous.

  • Eversept Partners's largest Q2 2024 buy was Insmed: 1,155,588 shares worth $77.4M.
  • Eversept Partners added most to Repligen in Q2 2024, an estimated $29.2M increase.
  • Eversept Partners's biggest Q2 2024 reduction was Natera, cutting an estimated $61.4M.
  • Eversept Partners fully exited Pfizer in Q2 2024, selling an estimated $30.6M.
  • Eversept Partners's ten largest holdings make up 61% of its $1.46B portfolio in Q2 2024.
  • Eversept Partners opened 16 new positions and closed 12 in Q2 2024.
  • Eversept Partners's portfolio value fell 2.6% quarter-over-quarter to $1.46B.

Based on Eversept Partners's 13F filing for Q2 2024, filed 14 Aug 2024.